Compartmental Pharmacokinetics and Tissue Distribution of Multilamellar Liposomal Nystatin in Rabbits

ABSTRACT The plasma pharmacokinetics of multilamellar liposomal nystatin were studied in normal, catheterized rabbits after single and multiple daily intravenous administration of dosages of 2, 4, and 6 mg/kg of body weight, and drug levels in tissues were assessed after multiple dosing. Concentrations of liposomal nystatin were measured as those of nystatin by a validated high-performance liquid chromatography method, and plasma concentration data were fitted into a two-compartment open model. Across the investigated dosage range, liposomal nystatin demonstrated nonlinear kinetics with more than proportional increases in the AUC0–24 and decreasing clearance, consistent with dose-dependent tissue distribution and/or a dose-dependent elimination process. After single-dose administration, the meanCmax increased from 13.07 μg/ml at 2 mg/kg to 41.91 μg/ml at 6 mg/kg (P < 0.001); the AUC0–24 changed from 11.65 to 67.44 μg · h/ml (P < 0.001), the Vd changed from 0.205 to 0.184 liters/kg (not significant), the CLt from 0.173 to 0.101 liters/kg · h (P < 0.05), and terminal half-life from 0.96 to 1.51 h (P < 0.05). There were no significant changes in pharmacokinetic parameters after multiple dosing over 14 days. Assessment of tissue concentrations of nystatin near peak plasma levels after multiple dosing over 15 days revealed preferential distribution to the lungs, liver, and spleen at that time point. Substantial levels were also found in the urine, raising the possibility that renal excretion may play a significant role in drug elimination. Liposomal nystatin administered to rabbits was well tolerated and displayed nonlinear pharmacokinetics, potentially therapeutic peak plasma concentrations, and substantial penetration into tissues. Pharmacokinetic parameters were very similar to those observed in patients, thus validating results derived from infection models in the rabbit and allowing inferences to be made about the treatment of invasive fungal infections in humans.

[1]  E. Hazen,et al.  Two antifungal agents produced by a soil actinomycete. , 1950, Science.

[2]  S. Piscitelli,et al.  High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[3]  G. Lopez-Berestein,et al.  Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.

[4]  G. Lopez-Berestein,et al.  Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. , 1990, The Journal of infectious diseases.

[5]  G. Lopez-Berestein,et al.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.

[6]  S. Piscitelli,et al.  Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits , 1999, Antimicrobial Agents and Chemotherapy.

[7]  R L Juliano,et al.  Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections , 1987, Antimicrobial Agents and Chemotherapy.

[8]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[9]  M. Kazemi,et al.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma , 1997, Antimicrobial agents and chemotherapy.

[10]  T. Walsh,et al.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.

[11]  V. Andriole.  HISTORY OF ANTIFUNGAL THERAPY , 1998 .

[12]  K. Olsen,et al.  Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis , 1994, Antimicrobial Agents and Chemotherapy.

[13]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[14]  Chemistry and biology of the polyene macrolide antibiotics. , 1973, Bacteriological reviews.

[15]  G. Lopez-Berestein,et al.  Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis , 1987, Antimicrobial Agents and Chemotherapy.

[16]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[17]  J. Ojwang,et al.  Comparison of In Vitro Antifungal Activities of Free and Liposome-Encapsulated Nystatin with Those of Four Amphotericin B Formulations , 1998, Antimicrobial Agents and Chemotherapy.

[18]  E. Anaissie,et al.  Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice , 1997, Antimicrobial agents and chemotherapy.

[19]  J. Hamilton-miller.  Chemistry and biology of the polyene macrolide antibiotics , 1973, Bacteriological reviews.

[20]  J. Bolard,et al.  Carrier effects on biological activity of amphotericin B , 1996, Clinical microbiology reviews.

[21]  S. Piscitelli,et al.  Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. , 1999, The Journal of antimicrobial chemotherapy.

[22]  D. Denning,et al.  Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B , 1999, Antimicrobial Agents and Chemotherapy.

[23]  K. Wasan,et al.  Species Differences in the Proportion of Plasma Lipoprotein Lipid Carried by High-Density Lipoproteins Influence the Distribution of Free and Liposomal Nystatin in Human, Dog, and Rat Plasma , 1999, Antimicrobial Agents and Chemotherapy.